Description

Vertex’s $4.9 Billion Alpine Immune Sciences Acquisition Is Suddenly Looking Brilliant

Vertex Pharmaceuticals demonstrated robust financial performance in 2025, marked by consistent revenue growth and strategic expansion efforts. The company reported a 10% increase in fourth-quarter revenue compared to the previous year, with total annual revenue reaching $12 billion, representing a 9% increase from 2024. The cystic fibrosis (CF) franchise remains a cornerstone, contributing significantly to Vertex’s financial health, with an 11% revenue rise in the United States driven by increased pediatric uptake and the launch of new CF therapies. International CF revenue saw a modest 2% growth amidst challenges such as a decline in revenue from Russia. Vertex’s newly launched products CASGEVY and JOURNAVX achieved $54 million and $27 million in fourth-quarter revenues, respectively, indicating strong initial market reception. The company anticipates further penetration and growth from these products, targeting over $500 million in non-CF revenue contribution for 2026.